A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Anifrolumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Registrational
- Acronyms TULIP SLE LTE
- Sponsors AstraZeneca
- 05 Dec 2017 Planned End Date changed from 14 Jun 2021 to 30 Nov 2021.
- 05 Dec 2017 Planned primary completion date changed from 14 Jun 2021 to 30 Nov 2021.
- 14 Jul 2016 Status changed from not yet recruiting to recruiting.